Endothelial progenitor cells and in-stent restenosis

Current Stem Cell Research and Therapy

Volumn 10, Issue 4, 2015, Pages 364-371

  Xu, Bu Yun ^a   Xiang, Mei Xiang ^a   Wang, Jian An ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Coronary heart disease; Endothelial cell; Endothelial progenitor cell; Endothelium injury; In stent restenosis; Percutaneous coronary intervention

Indexed keywords

ARTICLE; BARE METAL STENT; CELL THERAPY; DEVICE THERAPY; DRUG ELUTING STENT; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM INJURY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTENOSIS; REVASCULARIZATION; ANIMAL; CELL DIFFERENTIATION; CELL MOTION; CORONARY ARTERY DISEASE; CYTOLOGY; INJURIES; PHYSIOLOGY; STENT; VASCULAR ENDOTHELIUM;

ANIMALS; CELL DIFFERENTIATION; CELL MOVEMENT; CORONARY ARTERY DISEASE; ENDOTHELIAL PROGENITOR CELLS; ENDOTHELIUM, VASCULAR; HUMANS; STENTS;

EID: 84930516470     PISSN: 1574888X     EISSN: None     Source Type: Journal    
DOI: 10.2174/1574888X10666150204150430     Document Type: Article

References (85)

1. Rajendran P, Rengarajan T, Thangavel J, et al. The vascular endothelium and human diseases. Int J Biol Sci 2013; 9: 1057-69.
2. Ross R. Atherosclerosis is an inflammatory disease. Am Heart J 1999; 138: S419-20.
3. Vita JA. Endothelial function. Circulation 2011; 124: e906-12.
4. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75.
5. Jukema JW, Verschuren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 2012; 9: 53-62.
6. Farb A, Sangiorgi G, Carter AJ, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99: 44-52.
7. Grewe PH, Deneke T, Holt SK, Machraoui A, Barmeyer J, Muller KM. Scanning electron microscopic analysis of vessel wall reactions after coronary stenting. Z Kardiol 2000; 89: 21-7.
8. Chaabane C, Otsuka F, Virmani R, Bochaton-Piallat ML. Biological responses in stented arteries. Cardiovasc Res 2013; 99: 353-63.
9. Willis AI, Pierre-Paul D, Sumpio BE, Gahtan V. Vascular smooth muscle cell migration: current research and clinical implications. Vasc Endovascular Surg 2004; 38: 11-23.
10. Shiode N, Shirota K, Tsunoda F, Kato Y, Fujiwara M, Mimura A. Late progression after sirolimus-eluting stent implantation for de novo lesions--comparison with bare metal stent implantation. Circ J 2010; 74: 1104-10.
11. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drugeluting stents. J Am Coll Cardiol 2011; 57: 1314-22.
12. Kang SJ, Mintz GS, Akasaka T, et al. Optical coherence tomographic analysis of in-stent neoatherosclerosis after drug-eluting stent implantation. Circulation 2011; 123: 2954-63.
13. Vergallo R, Yonetsu T, Uemura S, et al. Correlation between degree of neointimal hyperplasia and incidence and characteristics of neoatherosclerosis as assessed by optical coherence tomography. Am J Cardiol 2013; 112: 1315-21.
14. Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
15. Yoneda S, Abe S, Kanaya T, et al. Late-phase inflammatory response as a feature of in-stent restenosis after drug-eluting stent implantation. Coron Artery Dis 2013; 24: 368-73.
16. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious. Circulation 2004; 109: 701-5.
17. Guagliumi G, Sirbu V, Musumeci G, et al. Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging. JACC Cardiovasc Interv 2012; 5: 12-20.
18. Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007; 115(18): 2435-41.
19. Simard T, Hibbert B, Ramirez FD, Froeschl M, Chen YX, O'Brien ER. The evolution of coronary stents: a brief review. Can J Cardiol 2014; 30(1): 35-45.
20. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-7.
21. Asahara T, Kawamoto A, Masuda H. Concise review: Circulating endothelial progenitor cells for vascular medicine. Stem Cells 2011; 29: 1650-5.
22. Masuda H, Alev C, Akimaru H, et al. Methodological development of a clonogenic assay to determine endothelial progenitor cell potential. Circ Res 2011; 109: 20-37.
23. Ramos AL, Darabi R, Akbarloo N, et al. Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. Circ Res 2010; 107: 1460-9.
24. Kawamoto A, Iwasaki H, Kusano K, et al. CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation 2006; 114: 2163-9.
25. Case J, Mead LE, Bessler WK, et al. Human CD34+AC133+VEGFR-2+ cells are not endothelial progenitor cells but distinct, primitive hematopoietic progenitors. Exp Hematol 2007; 35: 1109-18.
26. Ohtani K, Vlachojannis GJ, Koyanagi M, et al. Epigenetic regulation of endothelial lineage committed genes in pro-angiogenic hematopoietic and endothelial progenitor cells. Circ Res 2011; 109: 1219-29.
27. Sata M, Saiura A, Kunisato A, et al. Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis. Nat Med 2002; 8: 403-9.
28. Kawamoto A, Gwon HC, Iwaguro H, et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 2001; 103: 634-7.
29. Padfield GJ, Newby DE, Mills NL. Understanding the role of endothelial progenitor cells in percutaneous coronary intervention. J Am Coll Cardiol 2010; 55: 1553-65.
30. Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348: 593-600.
31. Hur J, Yoon CH, Kim HS, et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arterioscler Thromb Vasc Biol 2004; 24: 288-93.
32. Yoder MC, Mead LE, Prater D, et al. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007; 109: 1801-9.
33. Friedrich EB, Walenta K, Scharlau J, Nickenig G, Werner N. CD34-/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006; 98: e20-5.
34. Fujiyama S, Amano K, Uehira K, et al. Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells. Circ Res 2003; 93: 980-9.
35. Werner N, Junk S, Laufs U, et al. Intravenous transfusion of endothelial progenitor cells reduces neointima formation after vascular injury. Circ Res 2003; 93: e17-24.
36. Nowak G, Karrar A, Holmen C, et al. Expression of vascular endothelial growth factor receptor-2 or Tie-2 on peripheral blood cells defines functionally competent cell populations capable of reendothelialization. Circulation 2004; 110: 3699-707.
37. Hu CH, Ke X, Chen K, Yang DY, Du ZM, Wu GF. Transplantation of human umbilical cord-derived endothelial progenitor cells promotes re-endothelialization of the injured carotid artery after balloon injury in New Zealand white rabbits. Chin Med J (Engl) 2013; 126(8): 1480-5.
38. Walter DH, Rittig K, Bahlmann FH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 2002; 105: 3017-24.
39. Peichev M, Naiyer AJ, Pereira D, Zhu Z, et al. Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 2000; 95: 952-8.
40. Jiang S, Walker L, Afentoulis M, et al. Transplanted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci USA 2004; 101: 16891-6.
41. Lev EI, Leshem-Lev D, Mager A, et al. Circulating endothelial progenitor cell levels and function in patients who experienced late coronary stent thrombosis. Eur Heart J 2010; 31(21): 2625-32.
42. Griese DP, Ehsan A, Melo LG, et al. Isolation and transplantation of autologous circulating endothelial cells into denuded vessels and prosthetic grafts: implications for cell-based vascular therapy. Circulation 2003; 108: 2710-5.
43. Kong D, Melo LG, Mangi AA, et al. Enhanced inhibition of neointimal hyperplasia by genetically engineered endothelial progenitor cells. Circulation 2004; 109: 1769-75.
44. Griese DP, Achatz S, Batzlsperger CA, et al. Vascular gene delivery of anticoagulants by transplantation of retrovirally-transduced endothelial progenitor cells. Cardiovasc Res 2003; 58: 469-77.
45. Imamura H, Ohta T, Tsunetoshi K, et al. Transdifferentiation of bone marrow-derived endothelial progenitor cells into the smooth muscle cell lineage mediated by tansforming growth factor-beta1. Atherosclerosis 2010; 211: 114-21.
46. George J, Herz I, Goldstein E, et al. Number and adhesive properties of circulating endothelial progenitor cells in patients withinstent restenosis. Arterioscler Thromb Vasc Biol 2003; 23: 57e–60e.
47. Schober A, Hoffmann R, Opree N, et al. Peripheral CD34+cells and the risk of in-stent restenosis in patients with coronary heart disease. Am J Cardiol 2005; 96: 1116-22.
48. Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med 2006; 45: 581-7.
49. Inoue T, Sata M, Hikichi Y, et al. Mobilization of CD34 positive bone marrow-derived cells after coronary stent implantation: impact on restenosis. Circulation 2007; 115: 553-61.
50. Lei LC, Huo Y, Li JP, et al. Activities of circulating endothelial progenitor cells in patients with in-stent restenosis. Zhonghua Yi Xue Za Zhi 2007; 87: 3394-8.
51. Pelliccia F, Cianfrocca C, Rosano G, Mercuro G, Speciale G, Pasceri V. Role of endothelial progenitor cells in restenosis and progression of coronary atherosclerosis after percutaneous coronary intervention: a prospective study. JACC Cardiovasc Interv 2010; 3: 78-86.
52. Bonello L, Harhouri K, Baumstarck K, et al. Mobilization of CD34+KDR+ endothelial progenitor cells predicts target lesion revascularization. J Thromb Haemost 2012; 10: 1906-13.
53. Haine SE, Van Craenenbroeck EM, Hoymans VY, et al. Levels of circulating CD34+/KDR+ cells do not predict coronary in-stent restenosis. Can J Cardiol 2014; 30: 102-8.
54. Skowasch D, Jabs A, Andrie R, Dinkelbach S, Luderitz B, Bauriedel G. Presence of bone-marrow-and neural-crest-derived cells in intimal hyperplasia at the time of clinical in-stent restenosis. Cardiovasc Res 2003; 60: 684-91.
55. Frid MG, Kale VA, Stenmark KR. Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis. Circ Res 2002; 90: 1189-96.
56. Miyata T, Iizasa H, Sai Y, Fujii J, Terasaki T, Nakashima E. Platelet-derived growth factor-BB (PDGF-BB) induces differentiation of bone marrow endothelial progenitor cell-derived cell line TRBME2 into mural cells, and changes the phenotype. J Cell Physiol 2005; 204: 948-55.
57. Wang CH, Hsieh IC, Cherng WJ, et al. Differentiation profile of peripheral blood-derived vascular progenitor cell predicts intimal hyperplasia after coronary stenting. Heart Vessels 2012; 27(1): 10-9.
58. Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era. J Clin Pathol 2006; 59: 232-9.
59. Sieveking DP, Buckle A, Celermajer DS, Ng MK. Strikingly different angiogenic properties of endothelial progenitor cell subpopulations: insights from a novel human angiogenesis assay. J Am Coll Cardiol 2008; 51: 660-8.
60. Everaert BR, Van Craenenbroeck EM, Hoymans VY, et al. Current perspective of pathophysiological and interventional effects on endothelial progenitor cell biology: focus on PI3K/AKT/eNOS pathway. Int J Cardiol 2010; 144: 350-66.
61. Prasad K. Do statins have a role in reduction/prevention of post-PCI restenosis. Cardiovasc Ther 2013; 31: 12-26.
62. Okada T, Yamamoto H, Okimoto T, et al. Beneficial effects of valsartan on target lesion revascularization after percutaneous coronary interventions with bare-metal stents. Circ J 2011; 75: 1641-8.
63. Kun X, Yong L, Bo J, Hai-Ming S. Neointimal hyperplasia inhibition effect of angiotensin II type 1 receptor blockers in patients after coronary stent implantation: a meta-analysis. Am J Cardiovasc Drugs 2011; 11: 209-13.
64. Fan L, Chen L, Chen X, Fu F. A meta-analysis of stem cell mobilization by granulocyte colony-stimulating factor in the treatment of acute myocardial infarction. Cardiovasc Drugs Ther 2008; 22: 45-54.
65. Stein A, Mohr F, Laux M, et al. Erythropoietin-induced progenitor cell mobilisation in patients with acute ST-segment-elevation myocardial infarction and restenosis. Thromb Haemost 2012; 107: 769-74.
66. Ye H, He F, Fei X, et al. High-Dose Atorvastatin Reloading Before Percutaneous Coronary Intervention Increased Circulating Endothelial Progenitor Cells and Reduced Inflammatory Cytokine Expression During the Perioperative Period. J Cardiovasc Pharmacol Ther 2014; 19(3): 290-5.
67. Hibbert B, Simard T, Ramirez FD, Pourdjabbar A, Raizman JE, Maze R. The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J Cardiovasc Pharmacol 2013; 62(5): 491-6.
68. Assmus B, Urbich C, Aicher A, et al. HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 2003; 92(9): 1049-55.
69. Spyridopoulos I, Haendeler J, Urbich C, et al. Statins enhance migratory capacity by upregulation of the telomere repeat-binding factor TRF2 in endothelial progenitor cells. Circulation 2004; 110(19): 3136-42.
70. den Dekker WK, Houtgraaf JH, Onuma Y, et al. Final results of the HEALING IIB trial to evaluate a bio-engineered CD34antibody coated stent (GenousTMStent) designed to promote vascular healing by capture of circulating endothelial progenitor cells in CAD patients. Atherosclerosis 2011; 219(1): 245-52.
71. Kang HJ, Kim HS, Zhang SY, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocytecolony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751-6.
72. Bartunek J, Vanderheyden M, Vandekerckhove B, et al. Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112: I178-83.
73. van Beusekom HM, Ertas G, Sorop O, et al. The Genous endothelial progenitor cell capture stent accelerates stent reendothelialization but does not affect intimal hyperplasia in porcine coronary arteries. Catheter Cardiovasc Interv 2012; 79(2): 231-42.
74. Larsen K, Cheng C, Tempel D, et al. Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bioengineered stent in human ex vivo shunt and rabbit denudation model. Eur Heart J 2012; 33(1): 120-8.
75. Bystroň M, Cervinka P, Spaček R, et al. Randomized comparison of endothelial progenitor cells capture stent versus cobaltchromium stent for treatment of ST-elevation myocardial infarction. Six-month clinical, angiographic, and IVUS follow-up. Catheter Cardiovasc Interv 2010; 76: 627-31.
76. Beijk MA, Klomp M, van Geloven N, et al. Two-Year Follow-Up of the GenousTM Endothelial Progenitor Cell Capturing Stent Versus the Taxus Liberte´ Stent in Patients With De Novo Coronary Artery Lesions With a High-Risk of Restenosis: A Randomized, Single-Center, Pilot Study. Catheter Cardiovasc Interv 2011; 78: 189-95.
77. Beijk MA, Klomp M, Verouden NJ et al. GenousTM endothelial progenitor cell capturing stent vs. the Taxus Liberte´ stent in patients with de novo coronary lesions with a high-risk of coronary restenosis: a randomized,single-centre, pilot study. Eur Heart J 2010; 31: 1055-64.
78. Klomp M, Beijk MA, Koolen JJ, et al. 1-year outcome of TRIAS HR (TRI-stent adjudication study-high risk of restenosis) a multicenter, randomized trial comparing genous endothelial progenitor cell capturing stents with drug-eluting stents. JACC Cardiovasc Interv 2011; 4: 896-904.
79. Klomp M, Beijk MA, Koch KT, et al. One-year clinical outcome after provisional T-stenting for bifurcation lesions with the endothelial progenitor cell capturing stent compared with the bare-metal stent. Atherosclerosis 2010; 213: 525-31.
80. Chong E, Poh KK, Liang S, et al. Two-Year Clinical Registry Follow-up of Endothelial Progenitor Cell Capture Stent Versus Sirolimus-Eluting Bioabsorbable Polymer-Coated Stent Versus Bare Metal Stents in Patients Undergoing Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction. J Interv Cardiol 2010; 23(2): 101-8.
81. Nakazawa G, Granada JF, Alviar CL, et al. Anti-CD34 antibodies immobilized on the surface of sirolimus-eluting stents enhance stent endothelialization. JACC Cardiovasc Interv 2010; 3(1): 68-75.
82. Haude M, Lee SW, Worthley SG, et al. The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv 2013; 6(4): 334-43.
83. Fadini GP, Losordo D, Dimmeler S. Critical Reevaluation of Endothelial Progenitor Cell Phenotypes for Therapeutic and Diagnostic Use. Circ Res 2012; 110(4): 624-37.
84. Villa A, Arnold R, Sanchez PL, et al. Comparison of neointimal hyperplasia with drug-eluting stents versus bare metal stents in patients undergoing intracoronary bone-marrow mononuclear cell transplantation following acute myocardial infarction. Am J Cardiol 2009; 103: 1651-6.
85. Wong MM, Winkler B, Karamariti E, et al. Sirolimus stimulates vascular stem/progenitor cell migration and differentiation into smooth muscle cells via epidermal growth factor receptor/ extracellular signal-regulated kinase/β-catenin signaling pathway. Arterioscler Thromb Vasc Biol 2013; 33(10): 2397-406.